Thelansis’s “Glycogen Storage Disease Type 1a (GSD1a) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Glycogen storage disease type Ia (GSDIa) is an autosomal recessive disorder caused by biallelic G6PC variants that impair glucose-6-phosphatase activity, preventing the liver and kidneys from releasing glucose during fasting. Hypoglycemia may occur with lactic acidosis, hyperuricemia, hyperlipidemia, and hepatomegaly. Long-term complications include hepatic adenomas and kidney disease. Management requires individualized dietary planning, frequent complex-carbohydrate intake or uncooked cornstarch, monitoring, and treatment of complications; dietary care remains essential. In August 2026, the FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec), an AAV8 gene therapy, to reduce daily cornstarch intake as an adjunct to nutritional management in patients aged 8 years and older. It is not a cure or a substitute for diet, and confirmatory studies are required. Specialist monitoring is needed for liver toxicity, hypoglycemia, and other serious risks.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Glycogen Storage Disease Type 1a (GSD1a) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Glycogen Storage Disease Type 1a (GSD1a) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.